Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Portfolio Pulse from
Levi & Korsinsky law firm has notified shareholders of a class action lawsuit against Intellia Therapeutics (NTLA) for alleged securities fraud between July 30, 2024 and January 8, 2025. The lawsuit alleges that the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced a major reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
March 27, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Potential legal and financial risks emerge from class action lawsuit and major corporate reorganization, including research program cancellation and workforce reduction.
The class action lawsuit and corporate restructuring suggest significant operational challenges and potential financial strain for Intellia Therapeutics, likely to negatively impact investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100